文献速递炎症性肠病

系统综述与Meta分析:炎症性肠病中影响残疾的因素评估及炎症性肠病残疾指数可靠性

Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-09

该系统综述与Meta分析纳入9项横断面研究共3167例克罗恩病或溃疡性结肠炎患者,评估炎症性肠病残疾指数(IBD-DI)所测残疾的严重程度及相关因素并审查其效度。活动期患者残疾率高于缓解期(SMD=1.49,95%CI 1.11-1.88,I²=94%,P<.01),生物制剂治疗者残疾率低于糖皮质激素治疗者(SMD=-0.22,95%CI -0.36至-0.08,I²=0%,P<.01);疾病活动度和失业为相关因素。IBD-DI信效度良好,但可解释性仅适用于群体水平,需进一步研究测量其可解释性。

要点

  • 活动期患者残疾率高于缓解期(SMD=1.49,95%CI 1.11-1.88,I²=94%,P<.01)。
  • 生物制剂治疗者残疾率低于糖皮质激素治疗者(SMD=-0.22,95%CI -0.36至-0.08,I²=0%,P<.01)。
  • IBD-DI信效度良好,可解释性仅适用于群体水平,需进一步研究测量其可解释性。

核心结论

  • 系统综述与Meta分析发现疾病活动度、所接受治疗与残疾之间存在显著关联,但存在显著异质性。
  • IBD-DI可靠且有效,但需进一步研究测量其可解释性。

研究设计与样本

  • 系统综述与Meta分析,纳入9项横断面研究,共3167例溃疡性结肠炎或克罗恩病患者。
  • 患者按活动期、缓解期或需要手术、生物制剂和/或糖皮质激素治疗分类。
  • 纳入使用IBD-DI评估残疾且被电子和手工检索(2017年1月)捕获的研究,采用纽卡斯尔-渥太华量表评估偏倚可能性。

主要发现

  • 活动期患者残疾率高于缓解期患者(SMD=1.49,95%CI 1.11-1.88,I²=94%,P<.01)。
  • 生物制剂治疗患者残疾率低于糖皮质激素治疗患者(SMD=-0.22,95%CI -0.36至-0.08,I²=0%,P<.01)。
  • 疾病活动度和失业被确定为相关因素。
  • IBD-DI内部一致性评分为「良好」,评分者内信度为「一般」至「优秀」,评分者间信度为「优秀」。
  • 结构效度为「中等强度」至「非常强」,结构效度主要呈单维性;反应性优秀,可解释性仅在群体水平有用。

关键数值与推荐

  • 活动期 vs 缓解期残疾率:SMD=1.49(95%CI 1.11-1.88),I²=94%,P<.01。
  • 生物制剂 vs 糖皮质激素治疗残疾率:SMD=-0.22(95%CI -0.36至-0.08),I²=0%,P<.01。
  • IBD-DI内部一致性「良好」,评分者内信度「一般」至「优秀」,评分者间信度「优秀」。
  • 结构效度「中等强度」至「非常强」,结构效度主要呈单维性,反应性优秀,可解释性仅在群体水平有用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文报告存在显著异质性(活动期 vs 缓解期比较 I²=94%)。
  • IBD-DI的可解释性仅在群体水平有用,需进一步研究测量其可解释性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Inflammatory Bowel Disease Disability Index (IBD-DI) has recently been developed for patients with Crohn's disease (CD) and ulcerative colitis (UC). AIM: To assess the severity of disability and associated factors using the IBD-DI, and review the validity of the IBD-DI as a tool. METHOD: Systematic review of cross-sectional studies. Patients included had UC or CD and were classified as active, in remission, or needing surgery, biological and/or steroid treatment. We included studies assessing disability using the IBD-DI and that were captured by electronic and manual searches (January 2017). The possibility of bias was evaluated with the Newcastle-Ottawa Scale. RESULTS: Nine studies were included with 3167 patients. Comparatively, patients with active disease had higher disability rates than those in remission (SMD [CI95] = 1.49[1.11, 1.88], I2 = 94%, P<.01), while patients on biological treatment had lower disability rates than those receiving corticosteroid treatment (SMD [CI95] = -0.22[-0.36, -0.08], I2 = 0%, P<.01). Disease activity and unemployment were found to be associated factors. The IBD-DI scored "good" for internal consistency, "fair" to "excellent" for intra-rater reliability and "excellent" for inter-rater reliability. Construct validity was "moderately strong" to "very strong" and structural validity was found to be mainly unidimensional. The IBD-DI had excellent responsiveness, while its interpretability was only useful on a group level. CONCLUSIONS: This systematic review and meta-analysis found a significant association between disease activity, treatment received and disability; although significant heterogeneity was found. The IBD-DI is reliable and valid, but further studies are needed to measure its interpretability.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lo B, Prosberg MV, Gluud LL, et al. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Aliment Pharmacol Ther. 2017. PMID: 28994131. doi:10.1111/apt.14373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。